{"url_path":"/sec/allo/8-k/2026-06-22/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1737287/0001628280-26-044618-index.html","accession_number":"0001628280-26-044618","cik":"0001737287","ticker":"ALLO","issuer_name":"Allogene Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1737287/0001628280-26-044618-index.html","primary_entity_key":"0001737287","primary_entity_name":"Allogene Therapeutics, Inc."},"word_count":121,"has_tables":true,"body_markdown":"Item 8.01    Other Events.\n\nOn June 22, 2026, the Company filed a prospectus supplement (the \"Prospectus Supplement\") with the Securities and Exchange Commission relating to sales of shares of its common stock having an aggregate offering price of up to $135.0 million to be sold pursuant to a certain Sales Agreement, dated November 5, 2019, as amended on November 2, 2022 and November 2, 2023 (as amended, the \"Sales Agreement\"), by and between the Company and TD Securities (U.S.A.) LLC (f/k/a Cowen and Company, LLC).\n\nA copy of the legal opinion as to the legality of the shares issuable under the Sales Agreement and covered by the Prospectus Supplement is filed as Exhibit 5.1 to this Current Report on Form 8-K."}